MX2023002674A - Vacuna del tallo de ha para blancos positivos a anticuerpos ha. - Google Patents

Vacuna del tallo de ha para blancos positivos a anticuerpos ha.

Info

Publication number
MX2023002674A
MX2023002674A MX2023002674A MX2023002674A MX2023002674A MX 2023002674 A MX2023002674 A MX 2023002674A MX 2023002674 A MX2023002674 A MX 2023002674A MX 2023002674 A MX2023002674 A MX 2023002674A MX 2023002674 A MX2023002674 A MX 2023002674A
Authority
MX
Mexico
Prior art keywords
vaccine
influenza virus
vector
disease
against influenza
Prior art date
Application number
MX2023002674A
Other languages
English (en)
Inventor
Iwan Verstegen
Martijn Alexander Langereis
Haan Cornelis Alexander Maria De
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2023002674A publication Critical patent/MX2023002674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a vacunas contra la infección o enfermedad por el virus de la influenza para blancos con anticuerpos preexistentes contra el dominio de cabeza HA del virus de la influenza. La invención se refiere a un vector recombinante que expresa un polipéptido del tallo de HA, una vacuna que comprende el vector o una célula hospedera con dicho vector, usos del vector, la célula hospedera o la vacuna, y métodos para reducir la infección o enfermedad por el virus de la influenza. El vector recombinante puede ser un ácido nucleico tal como un plásmido de expresión eucariota o un ARN, un virus o una partícula de replicón (RP). Esta vacunación permite la inducción de una respuesta inmunitaria temprana y eficaz contra la infección o enfermedad inducida por el virus de la influenza, no obstaculizada por anticuerpos anti-dominio de cabeza HA preexistentes.
MX2023002674A 2020-09-07 2021-09-06 Vacuna del tallo de ha para blancos positivos a anticuerpos ha. MX2023002674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20194937 2020-09-07
PCT/EP2021/074446 WO2022049276A1 (en) 2020-09-07 2021-09-06 Ha stem vaccine for ha antibody-positive targets

Publications (1)

Publication Number Publication Date
MX2023002674A true MX2023002674A (es) 2023-04-03

Family

ID=72428193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002674A MX2023002674A (es) 2020-09-07 2021-09-06 Vacuna del tallo de ha para blancos positivos a anticuerpos ha.

Country Status (9)

Country Link
US (1) US20240024456A1 (es)
EP (1) EP4210740A1 (es)
JP (1) JP2023539771A (es)
KR (1) KR20230065321A (es)
CN (1) CN116528893A (es)
BR (1) BR112023004123A2 (es)
CA (1) CA3190070A1 (es)
MX (1) MX2023002674A (es)
WO (1) WO2022049276A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
CA2638746C (en) 2006-03-15 2014-12-02 Intervet International B.V. Recombinant mononegaviral virus vectors
PL2947149T3 (pl) 2007-06-21 2018-09-28 Alphavax, Inc. Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
HUE033739T2 (en) 2010-10-18 2018-01-29 Intervet Int Bv Turkey herpesvirus vector vaccine against avian influenza in poultry
ES2582324T3 (es) 2011-05-27 2016-09-12 20Med Therapeutics B.V. Nanogeles
MX357009B (es) 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
WO2016005482A1 (en) * 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof
US10428316B2 (en) 2014-12-04 2019-10-01 Intervet Inc. Immortalised chicken embryo fibroblasts
AR103245A1 (es) 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
US20200323975A1 (en) 2017-12-04 2020-10-15 Intervet Inc. Vaccination with replicon particles and oil adjuvant
MX2020006343A (es) 2017-12-20 2020-09-03 Intervet Int Bv Diluyente mejorado para vacuna de herpesvirus alfa asociado con celulas.

Also Published As

Publication number Publication date
BR112023004123A2 (pt) 2023-04-04
WO2022049276A1 (en) 2022-03-10
JP2023539771A (ja) 2023-09-19
EP4210740A1 (en) 2023-07-19
KR20230065321A (ko) 2023-05-11
US20240024456A1 (en) 2024-01-25
CA3190070A1 (en) 2022-03-10
CN116528893A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
MX2013004303A (es) Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral.
Wu et al. Comparative genomic analysis of duck enteritis virus strains
HRP20211015T1 (hr) Cjepivo protiv citomegalovirusa (cmv)
AR071910A1 (es) Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.
Boyd et al. Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus
US9901632B2 (en) Human herpesvirus immunotherapy
BR112015021974A2 (pt) Composição, e, método de indução de uma resposta imune
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
CO6140071A2 (es) Poxvirus de mapache que expresa glicoproteinas de la rabia
Cheng et al. Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
Wohlbold et al. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13
Li et al. Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail
Di Pilato et al. Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression
MX2023002674A (es) Vacuna del tallo de ha para blancos positivos a anticuerpos ha.
Maamary et al. Attenuated influenza virus construct with enhanced hemagglutinin protein expression
BRPI0904020B8 (pt) composição vacinal contra o vírus da dengue, e, kit
JP2018525028A5 (es)
WO2019029081A1 (zh) 干扰素κ在制备抗囊膜病毒药物方面的应用
EP3715459B1 (en) H9 avian influenza vaccine strain which differentiates infected from vaccinated animals, and preparation method therefor
BR112017024283A8 (pt) Vacinas contra a dengue
Avanthay et al. NS1 and PA-X of H1N1/09 influenza virus act in a concerted manner to manipulate the innate immune response of porcine respiratory epithelial cells
JP6373601B2 (ja) アカバネウイルスに対して中和活性を有する抗体を誘導するペプチド